delafloxacin (Quofenix)

following a full submission:

delafloxacin (Quofenix®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

SMC restriction: Patients with suspected or confirmed polymicrobial infection following treatment failure or when standard antibacterial therapies are not suitable. Delafloxacin should be used on the advice of local microbiologists or specialists in infectious disease.

In two randomised, phase III, double-blind studies in patients with ABSSSI, delafloxacin was non-inferior to a glycopeptide antibacterial plus a monocyclic beta-lactam antibiotic for clinical cure at the follow-up visit in the intention to treat population.